Cargando…
Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO)
BACKGROUND: This study was conducted to investigate a new short-course radiotherapy regimen for patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominant debilitating symptom. METHODS / DESIGN: This is an international, multi-center single arm prospective feasibil...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327575/ https://www.ncbi.nlm.nih.gov/pubmed/30630502 http://dx.doi.org/10.1186/s13014-019-1209-0 |